This document discusses anti-VEGF therapy as a first-line treatment for non-small cell lung cancer (NSCLC). It reports that sustained angiogenesis is a hallmark of solid tumors. Two studies, AVAiL and ECOG 4599, found that the addition of an anti-VEGF drug to chemotherapy improved progression-free survival for NSCLC patients compared to chemotherapy alone, with overall survival rates around 13 months. The document also lists common adverse events seen in one study of an anti-VEGF drug, including thromboembolism, hypertension, and bleeding. It concludes by thanking the audience.

1. Anti VEGF Therapy in first line
NSCLC
Dr. Rajib Bhattacharjee
Consultant Oncologist
Chittaranjan National Cancer Institute

3. Sustained Angiogenesis is one of the hallmark
feature of solid tumors

12. ORR 15% 35%

15. AVAiL Study

16. AVAiL PFS

17. AVAiL Efficacy
Overall Survival 13.1 13.6 13.4

19. ECOG 4599 v AVAiL Study

27. PFS EB–4.8mo E–3.7mo
HR-0.71(0.58-0.86) p<0.001

28. BEVERLY – BEVacizumab & ERLotinib
StudY

30. SAiL - Clinically significant (grade > 2) adverse
events
Thromboembolism 8%
Hypertension 6%
Bleeding 4%
Proteinuria 3%
Pulmonary hemorrhage 1%
Pulmonary embolism 1%
Epistaxis,
Neutropenia,
Febrile Neutropenia,
Deep Vein Thrombosis
1%

33. NCCN treatment algorithm for
advanced NSCLC

34. THANK YOU